These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8881387)

  • 21. Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.
    Hempel G; Boos J
    Oncologist; 2007 Aug; 12(8):924-6. PubMed ID: 17766651
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetically guided administration of chemotherapeutic agents.
    van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.
    Knezevic CE; Clarke W
    Ther Drug Monit; 2020 Feb; 42(1):6-19. PubMed ID: 31568180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
    de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.
    Kouno T; Katsumata N; Mukai H; Ando M; Watanabe T
    Jpn J Clin Oncol; 2003 Jun; 33(6):309-13. PubMed ID: 12913086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Individual dose adjustment in anticancer chemotherapy].
    Gamelin E; Boisdron-Celle M
    Rev Med Interne; 1996; 17(7):529-33. PubMed ID: 8881376
    [No Abstract]   [Full Text] [Related]  

  • 28. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of body surface area to calculate chemotherapeutic drug dose in dogs: II. Limitations imposed by pharmacokinetic factors.
    Frazier DL; Price GS
    J Vet Intern Med; 1998; 12(4):272-8. PubMed ID: 9686387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area.
    Mahmood I
    Eur J Drug Metab Pharmacokinet; 1996; 21(3):275-8. PubMed ID: 8980928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The scientific basis of body surface area-based dosing.
    Chatelut E; Puisset F
    Clin Pharmacol Ther; 2014 Apr; 95(4):359-61. PubMed ID: 24646485
    [No Abstract]   [Full Text] [Related]  

  • 32. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
    Hamada A
    Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scaling laws for plasma concentrations and tolerable doses of anticancer drugs.
    Dawson TH
    Cancer Res; 2010 Jun; 70(12):4801-8. PubMed ID: 20530681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose standardisation of anticancer drugs.
    Pouliquen AL; Escalup L; Jourdan N; Cottu P; Faure P; Madelaine-Chambrin I
    Int J Clin Pharm; 2011 Apr; 33(2):221-8. PubMed ID: 21369959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of population pharmacokinetic approach to clinical evaluation of anticancer agents].
    Tanigawara Y
    Gan To Kagaku Ryoho; 2001 May; 28(5):711-21. PubMed ID: 11383224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
    Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
    Cardoso E; Csajka C; Schneider MP; Widmer N
    Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cautious arguments in favor of body surface area-based dosing.
    Schuler U
    J Clin Oncol; 2002 Oct; 20(20):4270; author reply 4270-1. PubMed ID: 12377974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.